2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
10:30 a.m. - 12:00 p.m.
MCCNO - La Nouvelle A-B
Technology and Procedures, Omics Technologies, Bioinformatics, Computational Biology, Treatment Considerations, Combination Therapy, Adverse Events, Biological Processes, Apoptosis, Pathogenesis, CHIP, Genomics, Molecular Biology, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Research, Fundamental Science, Translational Research, Clinical Research, Study Population, Human, Adult
PAPER

822 Spatial multi-omics and intravital imaging identify macrophage-mediated T-cell sequestration as a driver of resistance to T-cell redirecting therapies in extramedullary multiple myeloma

Hyo Jeong Nam, Darwin D'Souza2, Kiana Chen, PhD3, Raina Roche4, Jing Zhang, MD5, Yunyun Qin, MD6, Jose A. Martinez-Climent, MD, PhD7, Emir Radkevich8, Chongfeng Bi9, Kai Nie10, Zhihong Chen, PhD11, Adolfo Aleman, PhD12, Christian Salib, MD13, Darren Pan, MD14, Ayala Lagziel, MD15, Dalit Hecht, MD16, Alessandro Lagana, PhD17, Adi Karlin, MD18, Rachel Brody, MD19, Tamir Shragai, MD20, Yael C. Cohen, MD21, David Fooksman, PhD22, Seunghee Kim-Schulze, PhD23, Samir Parekh, MD24
1 Icahn School of Medicine at Mount Sinai, New York, New York, United States
2 Icahn School of Medicine at Mount Sinai, New York, New York, United States
3 Albert Einstein College of Medicine, New York, New York, United States
4 Icahn School of Medicine at Mount Sinai, New York, New York, United States
5 University of Wisconsin-Madison, Madison, United States
6 Icahn School of Medicine at Mount Sinai, New York, New York, United States
7 University of Navarra, Pamplona, Spain
8 Icahn School of Medicine at Mount Sinai, New York, New York, United States
9 Icahn School of Medicine at Mount Sinai, New York, New York, United States
10 Icahn School of Medicine at Mount Sinai, New York, New York, United States
11 Icahn School of Medicine at Mount Sinai, New York, New York, United States
12 Icahn School of Medicine at Mount Sinai, New York, New York, United States
13 Icahn School of Medicine at Mount Sinai, New York, New York, United States
14 University of California at San Francisco, San Francisco, United States
15 Tel Aviv University, Tel Aviv, Israel
16 Tel Aviv University, Tel Aviv, Israel
17 Icahn School of Medicine at Mount Sinai, New York, United States
18 Tel Aviv University, Tel Aviv, Israel
19 Icahn School of Medicine at Mount Sinai, New York, New York, United States
20 Tel Aviv University, Tel Aviv, Israel
21 Tel Aviv University, Tel Aviv, Israel
22 Albert Einstein College of Medicine, New York, New York, United States
23 Icahn School of Medicine at Mount Sinai, New York, New York, United States
24 Icahn School of Medicine at Mount Sinai, New York, New York, United States

Background: Extramedullary disease (EMD) in multiple myeloma (MM) is associated with therapeutic resistance and poor outcomes. The spatial organization of the tumor microenvironment (TME) and the real-time cellular dynamics driving immune evasion in EMD remain poorly understood, representing a critical unmet clinical need.

Methods: High-resolution spatial profiling of 32 EMD samples from 29 patients treated with CAR-T or BiTEs, including 6 patients treated with dual-targeting BiTE (5 pre- and 1 post-treatment), was performed across anatomical sites using 10x Genomics Xenium spatial transcriptomics (5000 gene panel + 100 gene custom MM set) and spatial 17-marker proteomic profiling. To interrogate these spatial mechanics in real time, we visualized cellular dynamics of BCMA-targeted (tdTomato+) CAR-T mediated killing of High Risk (HR) MM in the tibia of immunocompetent mice with GFP+ 5080 cells (containing Trp53-/-; Bcl2-/- and NF-kBgof mutational profile) using two-photon time-lapse imaging.

Results: Human EMD biopsies were heavily dominated by Multiple Myeloma (MM) cells, comprising 60-90% of total cells. Target antigen expression exhibited marked heterogeneity; BCMA was broadly preserved on 70–95% of MMs across all EMD patients, whereas GPRC5D showed binary, all-or-none expression dynamics (0–85% of MM cells), complicating dual-targeting strategies. Following treatment, responders demonstrated higher overall T-cell proportions and an average 3.5-fold increase in CD8+ T-cell density diffusely infiltrating MM cells-dense tissue compared to non-responders. Conversely, non-responders exhibited striking T-cell exclusion from MM cells. Effector CD8+ T cells were instead sequestered alongside immunosuppressive SPP1+ and CD163+ macrophages and hypoxic fibroblasts in tumor-free intratumoral niches, a pattern we term the "macrophage-mediated T-cell sink." These niche macrophages expressed, driving CD8+ T-cell recruitment away from MM cells. CD8+ T cells within 20 µm of these macrophages exhibited significantly reduced Granzyme B expression.

Intravital two-photon imaging in HR MM mice functionally recapitulated this spatial sequestration and provided real-time mechanistic insight into CAR-T/BiTE failure. Time-lapse imaging revealed that while CAR-T cells were highly motile in the bone marrow parenchyma, they were repelled by large tumor masses, preventing intratumoral infiltration. In regions with smaller tumor burdens, CAR-T cells engaged in persistent cell-cell interactions with MM cells but failed to kill, indicating functional inactivation. Furthermore, imaging captured extensive CAR-T and MM cell clustering around bone marrow macrophages, accompanied by active transfer of vesicular material between MM cells and macrophages, directly linking myeloid interaction to local immune suppression.

Conclusions: Integrated spatial multi-omics of EMD and in vivo time-lapse bone marrow imaging demonstrate that resistance to T-cell immunotherapies is driven by the spatial sequestration of effector cells away from malignant plasma cells, mediated by immunosuppressive macrophages and chemotactic gradients. Disrupting these spatial immunosuppressive sinks represents a promising strategy to rescue T-cell cytotoxicity in refractory multiple myeloma.

Seunghee Kim-Schulze, PhD: No relevant conflicts of interest to declare.